Malagueule's Lounge

[malagueule]

OWCP DD

Authorized Shares 500,000,000 a/o Sep 23, 2016
Outstanding Shares 96,799,955 a/o Sep 23, 2016

Company only has 2 notes net of $51,969K which are mostly converted the past month

See below NO MORE TOXICS OWCP got $300k NON INTEREST BEARING LOAN WITH NO CONVERSION RIGHTS TO FUND OPERATIONS


OWCP an Israeli-based developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today announced it signed an agreement for $300,000 with Medmar LLC ("Medmar").

According to the terms of the agreement:

The funds will be allocated to complete the development of the Company's proprietary psoriasis cream;

Medmar will have exclusive right to manufacture, produce, publicize, promote and market OWC's Licensed Products in any state in the U.S;

The loan is non-interest bearing and will be repaid from royalties generated by the sale of OWC licensed products.

More details:
Medmar has agreed to loan OCW Ltd a total of $300,000 (the “Loan”) on a non-interest bearing basis, with no conversion rights. Medmar will fund the Loan in six equal installments of $50,000 each, as follows: (i) 1st installment was released to OWC Ltd on September 22, 2016; (ii) 2nd installment on October 1, 2016; (iii) 3rd installment on November 1, 2016; (iv) 4th installment on December 1, 2016; (v) 5th installment on January 1, 2017; and (vi) 6th installment on February 1, 2017. The Loan, as noted above, bears no interest, is not convertible, is due in 36 months from the Effective Date, and repayment shall be made only by the set off of royalties payable by Medmar to OWC Ltd.

PR:https://finance.yahoo.com/news/owc-pharmaceutical-research-corp-signs-120000921.html

8k: http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=11614519

!!OWC Looks to Bring Pharma-Grade Cannabis Therapeutics to Market!!

There are many different companies active in the medical marijuana industry, but few of them are conducting clinical research trials in accord with the Helsinki Committee Institutional Review Board protocols. Most investors are familiar with GW Pharmaceuticals plc (NASDAQ: GWPH) and its Sativex® cannabinoid medicine for the treatment of multiple sclerosis symptoms and cancer pain indications, but OWC Pharmaceutical Research Corp. (OTCQB: OWCP) is a lesser known company operating in the burgeoning industry.

Based in Israel, an international tech and biotech hub, and the epicenter of medical cannabis research, the OWCP is conducting clinical trials of cannabis-based treatments for multiple myeloma, psoriasis, fibromyalgia, post-traumatic stress disorder and migraines. The team is also working on several proprietary drug delivery mechanisms designed to provide consistent and reliable cannabinoid doses to patients more efficiently than smoking or consuming marijuana edibles.

Full Article below Please watch the interview: http://www.baystreet.ca/viewarticle.aspx?id=437873

99% of all CANNABIS RESEARCH IS BEING DONE IN ISREAL, OWCP IS AT THE EPICENTER OF THIS WORK


!!OWCP named one of top 20 Cannabis Stocks by Cannabis Investor Magazine!!

Cannabis Investor Magazine June Top 20 Cannabis Stocks

OWCP made the list huge recognition we are sitting on a goldmine.

https://finance.yahoo.com/news/cannabis-investor-magazine-june-top-130000276.htm

http://www.owcpharma.com/